Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive analysis of eosinophils and ILC2s in severe asthma treated with mepolizumab (MEISEA)
jRCT1031230460Recruiting
- Sponsor
- The Supported Studies Programme
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of mepolizumab in eosinophilic asthma (EA) (2 arms), sponsored by The Supported Studies Programme. Started Nov 2023; status: recruiting.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT1031230460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230460.